checkAd

     691  0 Kommentare Dynavax Receives Complete Response Letter from U.S. Food and Drug Administration for Biologics License Application for HEPLISAV-B - Seite 4

    (i) Schillie S, Murphy TV, Sawyer M, Ly K, Hughes E, et al. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management. MMWR. Recommendations and reports. Centers for Disease Control. 2013;62(RR-10):1-19.

    Lesen Sie auch

    Contact:
    Michael Ostrach
    Chief Financial Officer
    Dynavax
    Email contact


    Media Contact:
    Leslie Bryant
    WCG
    Email contact

    Diskutieren Sie über die enthaltenen Werte


    Seite 4 von 4

    Verfasst von Marketwired
    3 im Artikel enthaltene WerteIm Artikel enthaltene Werte
    Dynavax Receives Complete Response Letter from U.S. Food and Drug Administration for Biologics License Application for HEPLISAV-B - Seite 4 BERKELEY, CA--(Marketwired - November 14, 2016) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License …

    Artikel zu den Werten

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer